miR-217 and CAGE form feedback loop and regulates the response to anti-cancer drugs through EGFR and HER2

Youngmi Kim; Hyuna Kim; Deokbum Park; Minho Han; Hansoo Lee; Yun Sil Lee; Jongseon Choe; Young Myeong Kim; Dooil Jeoung

doi:10.18632/oncotarget.7185

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

miR-217 and CAGE form feedback loop and regulates the response to anti-cancer drugs through EGFR and HER2

Youngmi Kim, Hyuna Kim, Deokbum Park, Minho Han, Hansoo Lee, Yun Sil Lee, Jongseon Choe, Young Myeong Kim and Dooil Jeoung _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:10297-10321. https://doi.org/10.18632/oncotarget.7185

Metrics: PDF 2371 views | HTML 2335 views | ?

Abstract

Youngmi Kim1,*, Hyuna Kim1,*, Deokbum Park1,*, Minho Han1, Hansoo Lee2, Yun Sil Lee3, Jongseon Choe4, Young Myeong Kim4, Dooil Jeoung1

1Department of Biochemistry, College of Natural Sciences, Kangwon National University, Chunchon 200–701, Korea

2Department of Biological Sciences, College of Natural Sciences, Kangwon National University, Chunchon 200–701, Korea

3College of Pharmacy, Ewha Womans University, Seoul 03760, Korea

4Graduate School of Medicine, Kangwon National University, Chunchon 200–701, Korea

*These authors contributed equally to this work

Correspondence to:

Dooil Jeoung, e-mail: [email protected]

Keywords: anti-cancer drug-resistance, CAGE, EGFR, HER2, miR-217

Received: October 05, 2015 Accepted: January 23, 2016 Published: February 04, 2016

ABSTRACT

MicroRNA array analysis revealed that miR-217 expression was decreased in anti-cancer drug-resistant Malme3M^R cancer cells. CAGE, a cancer/testis antigen, was predicted as a target of miR-217. Luciferase activity and ChIP assays revealed a negative feedback relationship between CAGE and miR-217. miR-217 and CAGE oppositely regulated the response to anti-cancer drugs such as taxol, gefitinib and trastuzumab, an inhibitor of HER2. miR-217 negatively regulated the tumorigenic, metastatic, angiogenic, migration and invasion potential of cancer cells. The xenograft of Malme3M^R cells showed an increased expression of pEGFR^Y845. CAGE and miR-217 inhibitor regulated the expression of pEGFR^Y845. CAGE showed interactions with EGFR and HER2 and regulated the in vivo sensitivity to trastuzumab. The down-regulation of EGFR or HER2 enhanced the sensitivity to anti-cancer drugs. CAGE showed direct regulation of HER2 and was necessary for the interaction between EGFR and HER2 in Malme3M^R cells. miR-217 inhibitor induced interactions of CAGE with EGFR and HER2 in Malme3M cells. The inhibition of EGFR by CAGE-binding GTGKT peptide enhanced the sensitivity to gefitinib and trastuzumab and prevented interactions of EGFR with CAGE and HER2. Our results show that miR-217-CAGE feedback loop serves as a target for overcoming resistance to various anti-cancer drugs, including EGFR and HER2 inhibitors.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 7185

Publication Alerts

Research Papers:

miR-217 and CAGE form feedback loop and regulates the response to anti-cancer drugs through EGFR and HER2

Abstract